Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9Y2R0
UPID:
COA3_HUMAN
Alternative names:
Coiled-coil domain-containing protein 56; Mitochondrial translation regulation assembly intermediate of cytochrome c oxidase protein of 12 kDa
Alternative UPACC:
Q9Y2R0; A8K498
Background:
Cytochrome c oxidase assembly factor 3 homolog, mitochondrial, also known as Coiled-coil domain-containing protein 56, plays a pivotal role in the mitochondrial respiratory chain. It is a core component of the MITRAC complex, crucial for the regulation of cytochrome c oxidase assembly. This protein ensures the efficient translation of MT-CO1 and the assembly of mitochondrial respiratory chain complex IV, highlighting its essential function in cellular energy production.
Therapeutic significance:
The protein is linked to Mitochondrial complex IV deficiency, nuclear type 14, a disorder marked by developmental delay, cognitive impairment, and motor issues. Understanding the role of Cytochrome c oxidase assembly factor 3 homolog, mitochondrial could open doors to potential therapeutic strategies for this mitochondrial disorder, offering hope for targeted treatments.